Thiouracil: Comprehensive profile.

Q1 Pharmacology, Toxicology and Pharmaceutics Profiles of drug substances, excipients, and related methodology Pub Date : 2019-01-01 Epub Date: 2019-01-10 DOI:10.1016/bs.podrm.2018.11.006
Nasr Y Khalil, Haitham K AlRabiah, Mohammed S Almousa, Ahmed Bari, Hamad M Alkahtani
{"title":"Thiouracil: Comprehensive profile.","authors":"Nasr Y Khalil,&nbsp;Haitham K AlRabiah,&nbsp;Mohammed S Almousa,&nbsp;Ahmed Bari,&nbsp;Hamad M Alkahtani","doi":"10.1016/bs.podrm.2018.11.006","DOIUrl":null,"url":null,"abstract":"<p><p>Thiouracil, 2-sulfanylidene-1H-pyrimidin-4-one, has been used as anti-thyroid, coronary vasodilator, and in congestive heart failure. It was found to cause agranulocytosis and it is suspected to be teratogenic and carcinogenic. Owing to its high frequency of adverse reactions, especially agranulocytosis, its use was abandoned in favor of other, less toxic drugs, such as propylthiouracil and methimazole. Thiouracil refers both to a specific molecule consisting of a sulfated uracil and a family of molecules based upon the structure. An important member of this family is propylthiouracil, which is a thiourea antithyroid drug that acts by blocking the production of thyroid hormones; it also inhibits the peripheral deiodination of thyroxine to tri-iodothyronine. This profile is prepared to discuss and explain physical and chemical properties, proprietary and nonproprietary names of thiouracil and propylthiouracil. It also includes uses and applications, methods of preparation, thermal and spectral behavior and methods of analysis. In addition, metabolism, excretion and pharmacology of propylthiouracil are also discussed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"44 ","pages":"293-331"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.006","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Profiles of drug substances, excipients, and related methodology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.podrm.2018.11.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 1

Abstract

Thiouracil, 2-sulfanylidene-1H-pyrimidin-4-one, has been used as anti-thyroid, coronary vasodilator, and in congestive heart failure. It was found to cause agranulocytosis and it is suspected to be teratogenic and carcinogenic. Owing to its high frequency of adverse reactions, especially agranulocytosis, its use was abandoned in favor of other, less toxic drugs, such as propylthiouracil and methimazole. Thiouracil refers both to a specific molecule consisting of a sulfated uracil and a family of molecules based upon the structure. An important member of this family is propylthiouracil, which is a thiourea antithyroid drug that acts by blocking the production of thyroid hormones; it also inhibits the peripheral deiodination of thyroxine to tri-iodothyronine. This profile is prepared to discuss and explain physical and chemical properties, proprietary and nonproprietary names of thiouracil and propylthiouracil. It also includes uses and applications, methods of preparation, thermal and spectral behavior and methods of analysis. In addition, metabolism, excretion and pharmacology of propylthiouracil are also discussed.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
硫脲嘧啶:综合概况。
硫脲嘧啶,2-磺胺酰基- 1h -嘧啶-4- 1,已被用作抗甲状腺,冠状动脉血管扩张剂,并在充血性心力衰竭。它被发现会引起粒细胞缺乏症,并被怀疑是致畸和致癌的。由于其高频率的不良反应,特别是粒细胞缺乏症,它的使用被放弃,以支持其他毒性较小的药物,如丙硫脲嘧啶和甲巯咪唑。硫脲嘧啶既指由硫酸化尿嘧啶组成的特定分子,也指基于该结构的一系列分子。这个家族的一个重要成员是丙硫脲嘧啶,这是一种硫脲类抗甲状腺药物,通过阻断甲状腺激素的产生起作用;它也抑制外周甲状腺素脱碘为三碘甲状腺原氨酸。本简介旨在讨论和解释硫脲嘧啶和丙基硫脲嘧啶的物理和化学性质、专有和非专有名称。它还包括用途和应用,制备方法,热光谱行为和分析方法。此外,还讨论了丙硫脲嘧啶的代谢、排泄和药理学。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Profiles of drug substances, excipients, and related methodology
Profiles of drug substances, excipients, and related methodology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
13.10
自引率
0.00%
发文量
4
期刊最新文献
Avanafil: A comprehensive drug profile. Deferasirox: A comprehensive drug profile. Duvelisib: A comprehensive profile. Ponatinib: A comprehensive drug profile. Regorafenib: A comprehensive drug profile.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1